Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJuan DupontPZPier Luigi ZinzaniYXYan Xu

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows nemtabrutinib improved outcomes in relapsed marginal zone lymphoma, indicating a favorable safety profile.

Key Points

  • Evaluate the efficacy and safety of nemtabrutinib in patients with relapsed or refractory marginal zone lymphoma.
  • Multicenter, open-label, single-arm phase 2 trial (BELLWAVE-003)
  • Participants with relapsed or refractory marginal zone lymphoma received nemtabrutinib at 65 mg QD until disease progression or unacceptable toxicity
  • Primary endpoint: objective response rate; secondary endpoints: duration of response, safety.
  • Overall, 23 participants treated; median age was 68 years, with 43% male and 65% presenting with stage IV disease.
  • Objective response rates were 52% and 48% per independent review.
  • Median duration of response was 7.4 months; 55% of participants remained on treatment at data cut-off.
  • Adverse events included pneumonia (30%), pyrexia (30%), anemia (26%), and diarrhea (26%).

Cite This Study

Dupont et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d282https://doi.org/10.1182/blood-2025-1801
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study2025 · 1 citations
  2. 2BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).2024
  3. 3BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.2024 · 5 citations
  4. 4Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies.2026
  5. 5Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study2026 · 2 citations